Efficacy of SGLT2-inhibitors across different definitions of heart failure with preserved ejection fraction
Why the study?
SGLT2i have been evaluated in dedicated HF trials using detailed diagnostic criteria and in diabetic CVOTs relying on medical history, leaving efficacy across different definitions of HFpEF to be assessed.
Do SGLT2 inhibitors reduce cardiovascular death or heart failure hospitalization in patients with HFpEF across different diagnostic definitions?
Comparison
SGLT2i vs placebo
Authors
Discussion
Loading...
Member takes
Implication
SGLT2i reduce CV death or HF hospitalization in HFpEF regardless of diagnostic rigor; confirms consistent benefit across HF-RCTs and history-based CVOTs.
Structured PICO
Do SGLT2 inhibitors reduce cardiovascular death or heart failure hospitalization in patients with HFpEF across different diagnostic definitions?
P
Population
14,034 patients with heart failure and preserved ejection fraction (HFpEF) pooled from 7 RCTs (3 HF-RCTs: EMPEROR-Preserved, DELIVER, SOLOIST-WHF; and 4 CVOTs in diabetic patients: EMPA-REG OUTCOME, DECLARE-TIMI 58, VERTIS-CV, SCORED)
I
Intervention
SGLT2 inhibitors as a class
C
Comparator
Placebo
O
Outcome
Composite of cardiovascular death or heart failure hospitalization (HFH)composite
SGLT2 inhibitors consistently reduce cardiovascular death or heart failure hospitalization in patients with HFpEF, regardless of whether the diagnosis is based on strict trial criteria or medical history.
Cite This Study
Marzo et al. (2023) studied this question.